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Most viruses exploit a variety of host cellular proteins as primary cellular attachment receptors in the context of successful execution of
infection. Furthermore, many viral agents have evolved precise mechanisms to subvert host immune recognition to achieve persistence.
Herein we present data indicating that adenovirus (Ad) serotype 3 utilizes CD80 (B7.1) and CD86 (B7.2) as cellular attachment receptors.
CD80 and CD86 are co-stimulatory molecules that are present on mature dendritic cells and B lymphocytes and are involved in stimulating
T-lymphocyte activation. To our knowledge, this is one of the first demonstrations of a virus utilizing immunologic accessory molecules as a
primary means of cellular entry. This finding suggests a mechanism whereby viral exploitation of these proteins as receptors may achieve
both goals of cellular entry and evading the immune system.
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Adenoviruses (Ads) are nonenveloped, double-stranded
DNA viruses with icosahedral symmetry. There are 51
different human Ad serotypes, classified into six different
subgroups (A–F) based on their biological and genetic0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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E-mail address: david.curiel@ccc.uab.edu (D.T. Curiel).properties (Russell, 2000). Most Ad serotypes infect cells
via a two-step process: (i) Ad binding to a primary cellular
attachment receptor mediated by the distal knob domain of
one of the 12 fiber proteins extending from the Ad capsid
vertices (Louis et al., 1994), (ii) followed by the interaction
of aV integrins on the cell surface and the Ad penton base
RGD motif (Wickham et al., 1993). The initial binding of
Ad to its primary receptor is thought to be one of the key
determinants of virus tropism. The vast majority of the
serotypes, including Ad serotypes 2 (Ad2) and 5 (Ad5),
utilize the coxsackie and adenovirus receptor (CAR) as their
primary cellular attachment receptor (Bergelson et al., 1997;
Roelvink et al., 1998; Tomko et al., 2000). Ad2 and Ad5 are
the most thoroughly studied serotypes and the most com-
monly used Ad serotypes in gene therapy applications.
Of note in this regard, Ad have been exploited as a gene
transfer vector. Unfortunately, gene therapy protocols
employing Ad5-based vectors have resulted in limited effi-
cacies (Douglas et al., 2001). This may be in part due to
deficient/low CAR expression or inaccessibility of CAR on
the cell surface. CAR has been identified as a tumor
suppressor protein (Kim et al., 2003) and a member of the
Fig. 1. Identification of an 80-kDa protein band that selectively interacts
with the Ad3 fiber-knob domain. Three sample groups were generated and
ran on 10% SDS-PAGE: (1) CHO (C), HeLa (H), or U118-hCAR (U) cell
membranes; (2) the eluates from lysed HeLa cell membranes incubated with
an Ad3 fiber-knob domain-conjugated sepharose resin (H3), or an Ad5
fiber-knob domain-conjugated sepharose resin (H5); and (3) soluble CD86
(s86). Purified proteins were checked for the presence of CAR by Western
blot analysis with CAR extracellular domain specific rabbit polyclonal
antibodies (anti-CAR pAb). CAR (double arrows) was present in the
unpurified HeLa (H) and U118-hCAR (U) cell membranes and in the Ad5
fiber-knob domain-resin purified sample (H5). An unidentified protein
(single arrow) cross-reacted with polyclonal antibodies specific to the
extracellular domain of CAR. The polyclonal anti-CAR antibody also
cross-reacted with 3.75 Ag of the extracellular portion of CD86 (s86).
Protein marker (M, kDa).
Fig. 2. Identification of CD86 and comparison with CAR and CD80. (A)
Amino acid sequence of CD86. Proteins selected by affinity resins were
analyzed by mass spectrometry and N-terminal peptide sequencing. CD86
was identified by the peptide sequences obtained by N-terminal sequencing
(highlighted region) and by peptide fragments from the mass spectrometry
(underlined regions). (B) CAR, CD86, and CD80 homology. CAR and
CD86 exhibit homology (25.4% similarity, 16.4% identity) with the highest
region of homology occurring in the IgV-like domains (35.3% similarity,
25.5% identity). CAR and CD80 share less homology (22.0% similarity,
12.2% identity), but again have the highest degree of homology between
their IgV-like domains (34.6% similarity, 24.3% identity). * = CAR
residues involved in Ad5 fiber-knob domain binding.
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Therefore, CAR is often down-regulated in the context of
neoplastic conversion, and when expressed, its location basal
to the tight junction may limit its accessibility. Efforts to
circumvent these deficiencies have prompted the investiga-
tion of other non-CAR-binding Ad serotypes. One method of
accomplishing this is by the construction of pseudotype Ad
vectors (Krasnykh et al., 1996). Pseudotype Ad vectors
replace the fiber-knob domain of the Ad5 vector with the
fiber-knob domain from a non-CAR binding serotype, there-
by achieving serotype-specific infection of cells. Vectors
pseudotyped with the fiber-knob domain from Ad serotype
3 (Ad3), a member of subgroup B, efficiently transduce
malignant cells in a variety of neoplastic contexts (Davidoff
et al., 1999; Kanerva et al., 2002; Von Seggern et al., 2000),
as well as many other target cells of interest (Stevenson et al.,
1997). However, further development and characterization
of Ad3-based vectors have been hindered by the failure to
identify its primary cellular attachment receptor.
None of the subgroup B Ads, and several serotypes
from the other subgroups, utilize CAR as their primary
cellular attachment receptor (Roelvink et al., 1998). Sub-
group B is subdivided into two groups: B1, consisting of
serotypes 3, 7, 16, 21, and 50, and B2, consisting of
serotypes 11, 14, 34, and 35. Recently, it has been shown
that there are at least two subgroup B Ad receptors.
Viruses from subgroup B2 can fully inhibit the bindingof subgroup B1 viruses; however, viruses from subgroup
B1 can only partially inhibit the binding of subgroup B2
viruses (Segerman et al., 2003a). CD46 was identified as a
cellular attachment receptor for Ad serotypes 11 (Ad11)
and 35 (Ad35), both are members of the subgroup B2
(Gaggar et al., 2003; Segerman et al., 2003b). Additional-
ly, all of the subgroup B2 Ad as well as most of the
subgroup B1 Ad, with the exception of Ad3, are capable
of binding to CD46 expressed on the cell surface. How-
ever, only binding of the virions to CD46, not transduc-
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7 (Ad7), a member of subgroup B1, is capable of binding
to CD46; however, it cannot infect CD46-expressing
Chinese hamster ovary (CHO) cells, leading to the postu-
lation that CD46 serves as the subgroup B2-specific
receptor (Segerman et al., 2003b).
Although it has been observed that Ad3 pseudotype
vectors efficiently infect many cells of interest through an
alternate receptor than CAR (Stevenson et al., 1995), the
receptor responsible had yet to be identified (Di Guilmi et
al., 1995). We hypothesized that the Ad3 receptor could beFig. 3. The Ad3 fiber-knob domain specifically interacts with CD86 and CD80. (A
(gray profile) to HeLa, CHO, CHO-CD86, and CHO-CD80 cell lines detected via
but only the Ad3 fiber-knob domain bound specifically to CHO-CD86 and CHO
cells. (B) ELISA demonstrating the specific interaction between the recombinant
CD80 (sCD80) and CD86 (sCD86). Ad3 fiber-knob domain (n), Ad5 fiber-knobpurified from susceptible cells by using recombinant pro-
duced knob domain of the Ad3 fiber (Albiges-Rizo et al.,
1991) as an affinity agent. Collected proteins were ana-
lyzed by cross-reactivity with anti-CAR antibodies, mass
spectrometry, and N-terminal peptide sequencing. Further-
more, identified genes were introduced into cells resistant
to Ad3 infection to identify their role in conferring Ad3
infection. We identified two proteins, CD80 (B7.1) and
CD86 (B7.2), which demonstrated an interaction with the
knob domain of the Ad3 fiber and were capable of
mediating Ad3 infection of otherwise nonpermissive cells.) Binding of recombinant Ad3 (shaded profile) or Ad5 fiber-knob domain
flow cytometry. Both Ad3 and Ad5 fiber-knob domain bound to HeLa cells,
-CD80 cell lines. Neither Ad3 nor Ad5 fiber-knob domain bound to CHO
Ad3 fiber-knob domain and the soluble recombinant extracellular region of
domain (E), open symbols = sCD80, closed symbols = sCD86.
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Purification and identification of proteins that interact with
the knob domain of the Ad3 fiber
Membrane fractions from two cell lines that are efficiently
infected by Ad3 and Ad5, a human cervical carcinoma cell
line (HeLa) and a human malignant glioma cell line that
heterologously expresses CAR (U118-hCAR) (Kim et al.,
2003), were used as positive sources of Ad receptors. The
CHO cell line, which is poorly susceptible to Ad3 and Ad5
infection, was used as a negative control. Affinity resins were
generated by conjugating the recombinant knob domain of
Ad3 fiber or the Ad5 fiber to a sepharose resin, and proteins
were purified by incubating the resins with the cell membrane
fractions. To verify the technique, the resin conjugated to the
recombinant knob domain of the Ad5 fiber was used to purify
CAR. Western blot analysis of the affinity-purified proteins
demonstrated the isolation of CAR by the Ad5 fiber affinityFig. 4. CD80 and CD86 expression results in specific and enhanced gene transfer f
containing the Ad3 fiber-knob domain (Ad5/3luc1) or the Ad5 fiber-knob domai
(light gray bars), HeLa (black bars). * = significant difference vs. CHO cells ( P <
luciferase gene expression of vectors containing the Ad3 fiber-knob domain on CH
gray). (C) Recombinant Ad3 fiber-knob domain specifically blocks Ad5/3luc1 ge
cells (light gray). (D) Recombinant Ad5 fiber-knob domain has no effect on Ad5/3
CD86 cells (light gray). Relative light units (RLU), Error bars = FSD.resin (Fig. 1, double arrows). However, unexpectedly, an
approximately 80-kDa protein purified by the Ad3 fiber
affinity resin cross-reacted with the anti-CAR antibodies
(Fig. 1). The protein band specifically reacted with polyclonal
antibodies directed against the extracellular portion of CAR
and with a monoclonal anti-CAR antibody specifically di-
rected toward the CAR IgV-like domain (data not shown).
This protein was isolated and analyzed by mass spectrometry
and N-terminal peptide sequencing and identified as CD86
(Fig. 2A). CD86, also known as B7.2 (Caux et al., 1994;
Engel et al., 1994), is a member of the Ig superfamily and is a
co-stimulatorymolecule that interacts with CD28 and CTLA-
4 (Azuma et al., 1993). It has homology to CAR (16.4%
identity, 25.4% similarity) with the highest homology (25.5%
identity, 35.3% similarity) occurring between the IgV-like
domains (Fig. 2B).
CD80, also known as B7.1, is a member of the Ig
superfamily (Freeman et al., 1989) and interacts with the
same ligands as CD86 (Lanier et al., 1995). In this regardrom an Ad3 pseudotype vector. (A) Luciferase gene expression from vectors
n (Ad5luc1). CHO (white bars), CHO-CD80 (dark gray bars), CHO-CD86
0.05). (B) The extracellular domain of CD86 (sCD86) specifically inhibits
O cells (white), CHO-CD80 cells (dark gray), and CHO-CD86 cells (light
ne transfer. CHO cells (white), CHO-CD80 cells (dark gray), CHO-CD86
luc1 gene transfer. CHO cells (white), CHO-CD80 cells (dark gray), CHO-
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and CAR (Fig. 2B), we analyzed the role of CD80 in Ad3
infection. CD80 also exhibits homology to CAR (12.2%
identity, 22.2% similarity), with the highest degree of
homology seen between the IgV-like domains (Fig. 2B).
However, only 1 of the 16 amino acid residues critical for
the Ad5 fiber-knob binding to CAR (Bewley et al., 1999) is
conserved in each of CD80 and CD86, and only 3 residues
show similarity (Fig. 2B).
The knob domain of the Ad3 fiber specifically interacts with
CD80 and CD86
Using flow cytometry, the interaction of the knob domain
of the Ad3 fiber with CD80 and CD86 was demonstrated by
the ability of the recombinant knob domain of the Ad3 fiber
to specifically bind to CHO cells which heterologouslyFig. 5. CD80 and CD86-dependent infection by Ad3 pseudotype vectors. (A) CD
CHO, HeLa, CHO-CD80, and CHO-CD86 cells as assayed by flow cytometry. (B
anti-CAR antibodies block Ad5luc1 (C) gene transfer on HeLa (black), CHO (wh
CD80 or (F) anti-CD86 antibodies block CD80 or CD86-mediated gene transfer b
G). (H) Concurrent incubation with anti-CD80 and anti-CD86 antibodies results
Ad5luc1 (I). (B– I) HeLa (black), CHO (white), CHO-CD80 (dark gray), and CHexpress CD80 (CHO-CD80) or CD86 (CHO-CD86) (Vasu
et al., 2003) but not to the parent CHO cells (Fig. 3A). The
recombinant Ad5 fiber-knob domain showed no binding to
CHO, CHO-CD80, or CHO-CD86 cells (Fig. 3A). The
specificity of the Ad3 fiber-knob domain interaction with
CD80 and CD86 was additionally demonstrated by ELISA
(Fig. 3B), wherein a concentration-dependent binding to the
extracellular portion of CD80 (sCD80) and to the extracel-
lular portion of CD86 (sCD86) was seen for the Ad3 fiber-
knob domain and no binding was detected between sCD80
or sCD86 and the knob domain of the Ad5 fiber.
Heterologous expression of CD80 and CD86 permits
infection by Ad3-psuedotype vectors
The ability of CD80 and CD86 to confer susceptibility to
Ad3 infection was evaluated in CHO cells or CHO cells80 (dark gray, empty pattern) and CD86 (gray, filled pattern) expression on
) Anti-CAR antibodies do not block Ad5/3luc1 luciferase gene transfer, but
ite), CHO-CD80 (dark gray), and CHO-CD86 cells (light gray). (D) Anti-
y Ad3 pseudotype vectors, but have no effect on Ad5luc1 gene transfer (E,
in an increased inhibition of infection by Ad5/3luc1, but has no effect on
O-CD86 cells (light gray). Relative light units (RLU), Error bars = FSD.
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pseudotyped with the serotype 3 fiber-knob domain, thereby
specifically infecting via the Ad3 receptor and not via CAR,
and encoding the firefly luciferase transgene (Ad5/3luc1)
was used for the gene transfer analysis (Kanerva et al.,
2002). Infection of CHO-CD86 cells with the Ad5/3luc1
vector resulted in 10-fold greater reporter gene expression
compared to the parental CHO cells at all three MOIs: 10,
100, and 1000 virus particles per cell (vp/cell) (Fig. 4A).
The enhanced gene transfer was highly significant for all
three MOIs (P = 0.005, 0.011, 0.003, respectively). CHO-
CD80 cells showed an enhanced reporter gene expression of
4- to 5-fold, though never as high as the CHO-CD86 cells.
At an MOI of 10 vp/cell, the CHO-CD80 cells showed a
trend toward significance (P = 0.095), and a significantFig. 6. CD80 and CD86-dependent infection of human dendritic cells. (A) Lucif
(Ad5/3luc1) or the Ad5 fiber-knob domain (Ad5luc1) on immature and mature
vp/cell (black bars). (B) Anti-CAR antibodies specifically inhibit luciferase gene
specifically inhibit luciferase gene expression of vectors containing the Ad
background) Ad51/luc1, (gray background) immature dendritic cells (open symb
Error bars = FSD.difference at 100 and 1000 vp/cell for the Ad5/3luc1 vector
(P = 0.031 and 0.005, respectively). No significant differ-
ences in reporter gene expression were seen between the
CHO, CHO-CD80 (P = 0.115, 0.12, 0.151), or CHO-CD86
(P = 0.103, 0.161, 0.169) cells infected with an Ad5 vector
with an Ad5 fiber-knob domain (Ad5luc1) (Fig. 4A). The
low level of infection seen with the CHO cells, which do not
express the CD80, CD86, or CAR, is presumably due to the
secondary entry mechanism mediated by the RGD motif in
the Ad capsid and aV integrins on the cell surface, because
there is no difference in infectivity of the CHO cells by the
Ad5luc1 or Ad5/3luc1 vectors (Fig. 4A).
Ad5/3luc1 infection could be inhibited by 90% by
preincubation of the virus with the soluble CD86 (sCD86)
(Fig. 4B). This inhibition occurred by sCD86 binding to theerase gene expression from vectors containing the Ad3 fiber-knob domain
human dendritic cells. 1 vp/cell (white bars), 10 vp/cell (gray bars), 100
expression of Ad5 vectors. (C) Anti-CD80 and (D) anti-CD86 antibodies
3 fiber-knob domain on immature and mature dendritic cells. (white
ols) dendritic cells (diagonal-lined symbols). Relative light units (RLU),
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of the fiber with any cellular receptors. The inhibition seen
on the CHO cells is presumably due to the added steric
hindrance of the sCD86 attached to the virion, interfering
with penton base and integrin interactions. Finally, Ad5/
3luc1 gene transfer was specifically inhibited by preincu-
bation of the cells with recombinant Ad3 fiber-knob domain
(Fig. 4C), but not by recombinant Ad5 fiber-knob domain
(Fig. 4D). Therefore, Ad vectors targeted with the knob
domain of the Ad3 fiber specifically utilize CD80 and CD86
as primary cellular attachment receptors.
To further characterize the utilization of CD80 and CD86
by Ad3 pseudotype vectors (Ad5/3luc1), the ability to
specifically block infection by antibodies was investigated.
On the CHO cell derivatives, the anti-CAR antibodies had
no effect on either virus or any of the cell lines because
CAR is not expressed on any of the cells. Of note in this
regard, the monoclonal antibody used in these experiments,
RmcB, did not cross-react with CD80 or CD86 by Western
blot analysis (data not shown). Preincubation of HeLa cells
with anti-CAR antibodies effectively blocked Ad5 gene
transfer (Fig. 5C), but not Ad5/3luc1 gene transfer (Fig.
5B). Anti-CD80 and anti-CD86 antibodies were able to
specifically block the gene transfer of Ad3 pseudotype
vectors (Figs. 5D, 5F, and 5H) on the respective CHO
derivative and showed no effect on Ad5 vectors or the
CHO parental cells (Figs. 5E, 5G, and 5I). The Ad5/3luc1
gene transfer to the CHO cells correlated with the expres-
sion of CD80 and CD86 on the cell surface (Fig. 5A).
Preincubation of HeLa cells with anti-CD80 antibodies
blocked Ad5/3luc1 gene transfer by about 10% (Fig. 5D)
and preincubation with anti-CD86 antibodies blocked Ad5/
3luc1 gene transfer by about 25% (Fig. 5F). These inhib-
itions corresponded with the levels of receptor expression
on HeLa cells gathered by flow cytometry (Fig. 5A) and RT-
PCR (data not shown). Concurrent incubation of the HeLa
cells with anti-CD80 and anti-CD86 antibodies more effec-
tively blocked Ad5/3luc1 gene transfer but only by about
55% at the highest antibody concentration (Fig. 5H). It
appears that Ad3 pseudotype vectors may utilize CD80 and
CD86 on HeLa cells, but there remains a high probability of
a second primary receptor on these cells.
Adenoviral vectors containing the fiber-knob domain of
serotype 3 infect human dendritic cells through CD80 and
CD86
Adenoviral vectors containing the fiber-knob domain of
serotype 3 exhibited an enhanced infectivity compared to
Ad5 vectors on immature dendritic cells as well as an 8-fold
enhancement of Ad5/3luc1 infection of mature dendritic
cells vs. immature dendritic cells (Fig. 6A). Gene transfer
could also be partially inhibited by anti-CD80 and anti-CD86
antibodies, about 40% reduction by preincubation with anti-
CD80 antibodies and about 60% reduction by preincubation
with anti-CD86 antibodies. However, gene transfer mediatedby the Ad5 vectors was unaffected by preincubation of the
cells with anti-CD80 or anti-CD86 antibodies (Figs. 6C and
6D). However, the infection of Ad5 vectors could be
inhibited by preincubation of the cells with anti-CAR anti-
bodies, which had no effect on the Ad3 pseudotype vectors
(Fig. 6B). Here it appears that CD80 and CD86 serve as
cellular receptors utilized by Ad3 pseudotype vectors for
infection of human dendritic cells.Discussion
Our major finding is that Ad3 can utilize both CD80 and
CD86 as cellular attachment receptors. It appears that CD80
and CD86 may not be the only receptor utilized by Ad3 in
the infection of HeLa cells, whereas with human dendritic
cells, CD80 and CD86 provide a primary means of cellular
attachment. CD80 and CD86 are co-stimulatory molecules
that are primarily expressed on mature dendritic cells and
mature B lymphocytes. Additionally, they have been shown
to possess dysregulated expression on a variety of neo-
plasms (Brouwer et al., 2000; Koyama et al., 1998; Maeda
et al., 2000; Mutti et al., 1998; Tatsumi et al., 1997). Our
finding reconciles several recent reports in the literature.
First, it is consistent with the observation that the Ad fiber-
knob domain can elicit the maturation process of immature
dendritic cells (Rea et al., 1999) and that subgroup B vectors
are significantly better able to infect mature dendritic cells
compared to immature dendritic cells (Rea et al., 2001),
because both CD86 and CD80 are up-regulated during
dendritic cell maturation (Lapteva et al., 2001). Second,
Ad3 efficiently infects EBV-transformed B-cell lymphomas
(Von Seggern et al., 2000), which often overexpress CD80
and CD86 (Suvas et al., 2002; Widney et al., 2003). Third,
the subgroup B viruses efficiently infect cells of hemato-
poietic origin (Marini et al., 2002; Sakurai et al., 2003;
Segerman et al., 2000).
The use of subgroup B Ad vectors offers many advan-
tages in gene therapy and vaccine applications. The discov-
ery of the utilization of CD80 and CD86 by Ad3 is very
useful for the further development of these applications and
offers a more fundamental understanding of virus–cell
interactions that are critical for advancing these studies. A
further implication of our finding is that Ad3 pseudotype
vectors may offer an advantage in cancer gene therapy
protocols based on CD86 and CD80 dysregulation in the
context of neoplastic conversion. CD86 is generally up-
regulated in several neoplastic contexts, including gastric
carcinoma (Koyama et al., 1998), various lymphomas
(Brouwer et al., 2000; Freeman et al., 1989; Suvas et al.,
2002), and mesothelioma (Mutti et al., 1998), whereas
CD80 expression is either unaffected or down-regulated
(Koyama et al., 1998; Suvas et al., 2002).
The finding that Ad3 utilizes CD80 and CD86 as cellular
attachment receptors highlights the broad variation in the
functions of receptors utilized by Ad. CAR, which is utilized
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(Kim et al., 2003; Okegawa et al., 2000) and a component of
the adherens junction (Cohen et al., 2001; Walters et al.,
2002). It is a homophilic cell adhesion molecule that is
generally down-regulated in neoplastic conversion and plays
a role in brain development (Honda et al., 2000). CD46
(Membrane Cofactor Protein) which is used by Ad11 and
Ad35, is ubiquitously expressed and involved in the comple-
ment pathway (Gaggar et al., 2003; Segerman et al., 2003b).
Ad37, which is able to bind CAR but not use it as a receptor,
utilizes sialic acid residues as a receptor (Arnberg et al.,
2002), as well as an additional unidentified protein (Wu et al.,
2001). Ad5 can also infect cells by binding to theMHC class I
a2 domain (Hong et al., 1997) and a3h1 integrins (Salone et
al., 2003). There are at least two groups of subgroup B Ad
receptors (Segerman et al., 2003a), therefore, there may still
exist other receptors that may be utilized by subgroup B Ad.
This broad variation in receptor classes may further help to
explain the variation in viral tropism and pathogenesis
between the different serotypes.
Finally, the finding that Ad3 uses CD80 and CD86 as
cellular attachment receptors is to our knowledge one of
the first examples of a virus utilizing a co-stimulatory
molecule as a primary means of cellular entry. However,
precedent for this scenario is set by several viruses, such as
HIV-1 and hepatitis C, using the C-type lectin DC-sign
(dendritic cell-specific intercellular adhesion molecule-
grabbing) for entry into dendritic cells (van Kooyk and
Geijtenbeek, 2003). From a biological perspective, this
may allow the virus to escape the surveillance of the
immune system and further provide an advantage in
affecting immune response modulation. Normal virus rep-
lication biology includes the down-regulation of cell pro-
tein synthesis and disrupted cellular functions. Therefore,
due to the prevalence of CD80 and CD86 on antigen
presenting cells (APC), Ad3 may have evolved the utili-
zation of these molecules to infect APC as a means of
modulating an immune response to the viral infection. It is
unknown at this time what effect Ad3 infection has on the
native functions of CD80 and CD86. However, both
molecules are critical in stimulating T-cell responses and
any perturbations in their normal functions may disrupt T-
cell activation.Methods
Cell culture
Chinese hamster ovary cell line (CHO) and HeLa cell
line (both from ATCC, Manassas, VA) were grown in
DMEM/F12 50:50 with 10% FBS and antibiotics as rec-
ommended by the provider. Generation of CHO-CD80,
CHO-CD86, and U118-hCAR cell lines was previously
described (Kim et al., 2003; Vasu et al., 2003); the cells
were grown in the same media in the presence of geneticinat 400 Ag/ml. All cells were cultured in a humidified
incubator at 37 jC with 5% CO2.
Recombinant Ad
Two replication-incompetent Ad5-based vectors contain-
ing a firefly luciferase transgene cassette in place of the
deleted E1 region were used. Ad5luc1 contains the full Ad5
capsid and fiber proteins, whereas Ad5/3luc1 contains the
Ad5 capsid with chimeric fiber proteins in which the tail and
shaft domains are from Ad5 and the knob domain is from
Ad3. Both vectors were generated in our laboratory and
described previously (Kanerva et al., 2002).
Recombinant Ad3 and Ad5 fiber-knob domain protein
production
The fiber-knob domains of Ad5 and Ad3 fibers were
produced in Escherichia coli with N-terminal tags of six
consecutive histidine residues (6-HIS), using the pQE30
expression vector (Qiagen, Valencia, CA) (Krasnykh et al.,
1996). The soluble forms of the Ad3 and Ad5 fiber-knob
domain proteins were isolated from the induced E. coli
cultures using the BugBuster Protein Extraction Reagent
(Novagen, Madison, WI). The proteins were further purified
using the Talon metal affinity resin (Clontech, Palo Alto,
CA) as recommended by the manufacturer. To further
increase the protein yield, the expressed Ad3 fiber-knob
domain protein was purified from inclusion bodies using the
BugBuster Protein Extraction Reagent inclusion body pro-
tocol as recommended by the manufacturer. The concentra-
tion of the purified proteins was determined by the Bio-Rad
protein assay (Bio-Rad, Hercules, CA). The ability of each
Ad fiber-knob domain to form a homotrimer was verified by
Western blot of unboiled vs. boiled samples. Furthermore,
Ad fiber-knob domain function was confirmed by its ability
to inhibit Ad infection of the same serotype but not affect
infection of the other serotype.
Receptor purification and analysis
Affinity resins were generated by conjugating recombi-
nantly produced Ad3 fiber-knob or Ad5 fiber-knob to a
cyanogens-bromide activated sepharose resin (Sigma) as
directed by the manufacturer. Cell membrane fractions were
collected as previously described (Wu et al., 2001), and
incubated with the resins overnight at 4 jC in PBS with
Ca2+ and Mg2+ (PBSCM) plus 1% BSA plus protease
inhibitor cocktail (Sigma). Resins were then washed 3 times
with PBSCM and bound proteins were eluted with glyci-
ne:HCl (pH 2) for 10 min at 37 jC and then neutralized to a
neutral pH (pH 7). Samples were analyzed by SDS-PAGE
and Western blot with anti-CAR polyclonal antibodies [The
University of Alabama at Birmingham (UAB)] and anti-
CAR IgV-like domain-specific monoclonal antibody 9b3
(UAB Hybridoma Shared Facility, Birmingham, AL). Se-
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Mass Spectrometry Shared Facility and the UAB Peptide
Sequencing Shared Facility.
Flow cytometry
Cells were grown to approximately 85% confluency,
harvested with Versene, and incubated with Ad3 fiber-knob,
Ad5 fiber-knob, or without Ad fiber-knob in growth media
for 1 h at 4 jC. Cells were then washed 3 times in cold
(4 jC) PBSCM. Cells were next incubated with mouse
monoclonal anti-polyhistidine clone HIS-1 antibody (Sigma)
in PBSCM plus 1% BSA for 1 h at 4 jC. Cells were washed
3 times in cold PBSCM and incubated with anti-mouse IgG
antibodies conjugated to a fluorophore, Alexa 488 (Molec-
ular Probes, Eugene, OR), in PBSCM plus 1% BSA for 1 h at
4 jC. Alternatively, for the expression of CD80 and CD86,
specific polyclonal antibodies were used for each marker
(Santa Cruz Biotechnology, Santa Cruz, CA) with incuba-
tion for 1 h at 4 jC in PBS plus 1% BSA. Cells were washed
3 times in cold PBS and incubated with anti-rabbit IgG
antibodies conjugated to a fluorophore, Alexa 488 (Molec-
ular Probes). All of the cells were washed 3 final times in
cold PBSCM and analyzed by flow cytometry by the Center
for Aids Research FACS Core Facility at UAB.
Human dendritic cell purification
Human dendritic cells were derived from the peripheral
blood of normal donors, using a protocol approved by the
UAB Institutional Review Board. Peripheral blood mononu-
clear cells were purified with gradient centrifugation by using
Histopaque (Sigma Diagnostics, St. Louis, MO). CD14+
monocytes were then isolated by using CD14 Microbeads
and magnetic cell sorting (Miltenyi Biotec, Auburn, CA).
They were cultured for 6 days in RPMI 1640 medium with
10% FBS, 2 mM glutamine, 100 units of penicillin/ml, 100
Ag of streptomycin/ml, and 50 AM 2-mercaptoethanol con-
taining 100 ng of recombinant human interleukin-4 (R&D
Systems, Minneapolis, MN) and 100 ng of recombinant
human granulocyte-macrophage colony-stimulating factor
(Immunex, Seattle, WA)/ml. Maturation of a portion of the
dendritic cells was induced by adding LPS at a concentration
of 100 ng/ml to the media on the 5th day. Expression of
molecular markers typical of immature dendritic cells
(CD14 CD11c+ CD40+ CD86+ HLADR+) was confirmed
by staining with relevant monoclonal antibodies (MAbs).
ELISA
Indicated amounts of recombinant Ad3 fiber-knob or Ad5
fiber-knob were adsorbed in a 96-well plate for 30 min at
37 jC. Wells were then rinsed with Tris-buffered saline with
Tween 20 (TBST) and blocked with 5% casein in TBST for
30 min at 37 jC. After rinsing with TBST, 0.2 Ag/well of
recombinant extracellular domain of CD80 or CD86 fusedwith mouse Fc region (sCD80, sCD86) (Alexis Biochemi-
cals, Lausanne, Switzerland) in PBSCM plus 1% BSA was
added to each well for 30 min at 37 jC. Wells were then
washed 3 times with TBST and incubated with anti-mouse
IgG antibodies conjugated to alkaline phosphatase (DAKO
Corp.) in PBSCM plus 1% BSA for 30 min at 37 jC. Wells
were washed 3 times with TBST and developed with p-
nitrophenyl phosphate (Sigma). Alkaline phosphatase activ-
ity was assayed by measuring the optical density at 405 nm.
Gene transfer analysis
Cells were seeded in 12-, 24-, or 48-well plates and
allowed to grow until 85% confluence. The cells were then
incubated with either Ad5luc1 (1, 10, 100, or 1000 vp/cell),
Ad5/3luc1 (1, 10, 100, or 1000 vp/cell), or no virus in
DMEM:F12 50:50 with 2% FBS for 1.5 h at 37 jC. For
blocking experiments, (1) Ad5/3luc1 virus (100 vp/cell) was
preincubated in the presence of three different concentra-
tions of sCD86 (3.125, 6.25, 12.5 Ag/well) or (2) the cells
were preincubated with various antibodies: anti-CAR
(RmcB, ATCC), anti-CD80 (Santa Cruz Biotechnology),
or anti-CD86 (Santa Cruz Biotechnology), at three different
concentrations (5, 10, 20 Ag/ml) or anti-CD80 and anti-
CD86 (at 10, 20, 40 Ag/ml), or (3) the cells were preincu-
bated with recombinant Ad3 or Ad5 fiber-knob (0.1, 0.05,
0.025 mg/ml). For all blocking trials, incubation occurred
for 10 min at 37 jC before virus was incubated with the
cells for 1.5 h at 37 jC. Virus was then removed and the
cells were rinsed with PBS and grown in growth media for
36 h. After 36 h, the cells were lysed and the luciferase
assay was performed with the Luciferase Assay System
(Promega, Madison, WI). The protein concentration of the
cell lysates was determined with DC-Bio-Rad protein assay
to allow normalization of the gene expression data to the
number of cells. Background luciferase activities were
subtracted from the readings. All of the samples were done
in triplicate and the mean average, standard deviation, and P
values were calculated using Student’s t tests.Acknowledgments
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